Clinical Trial

Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this investigator-initiated study is to assess the efficacy of treating patellofemoral osteoarthritis with an Advanced Therapy Medicinal Product (ATMP), autologous nasal chondrocyte tissue engineered cartilage (N-TEC), in comparison with a standard therapy using platelet rich plasma injections. The engineered cartilage graft is obtained by culturing expanded autologous nasal chondrocytes within a collagen type I/III membrane.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-11-30; most recent amendment 2026-06-10.
Status change: Not Yet Recruiting → Recruiting 2024-06-10
Trial Details
NCT Number NCT06163573
Lead Sponsor University Hospital, Basel, Switzerland
Collaborators: Swiss National Science Foundation, Clinical Trial Unit, University Hospital Basel, Switzerland, Wuerzburg University Hospital
Conditions Patellofemoral Osteoarthritis
Enrollment 75 participants
Start Date 2024-06-06
Primary Completion 2028-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-11